Tromsø, Norway, June 16th, 2025 - ArcticZymes Technologies ASA (OSE:AZT) is
pleased to announce the expansion of its GMP product range, with the
introduction of M-SAN HQ GMP, a new GMP grade nuclease specifically designed for
viral vector manufacturing. This new product combines the proven performance of
M-SAN HQ with the regulatory robustness of GMP manufacturing, providing a highly
effective solution for enzymatic host cell DNA removal under physiological salt
conditions

Unlike traditional nucleases, M-SAN HQ retains high activity at physiological
salt concentrations (~150 mM), enabling direct use in cell culture media or
harvest supernatants without harsh buffer exchanges. This makes it well-suited
for the manufacture of fragile viral vectors such as lentiviruses and
retroviruses, which are critical components of many advanced therapies and
vaccine platforms.

With the launch of M-SAN HQ GMP, viral vector manufacturers can now benefit from
the unmatched performance of M-SAN HQ, while ensuring a seamless transition into
full-scale production.

With the emergence of new therapeutic strategies, such as in vivo CAR-T, the
need to reduce nuclease and host cell DNA contamination in the final product is
even more critical. M-SAN HQ GMP is perfectly positioned to answer this need,
supporting the therapies of the future.

CEO Michael B. Akoh comments:
"With the launch of M-SAN HQ GMP, we're bringing an important new product to the
market-an enzyme that performs optimally under physiological salt conditions and
meets GMP requirements, ensuring companies can quickly and easily move from
product development into full scale production.

This new product is a direct response to customer needs for technically advanced
and compliant nuclease that fit seamlessly into demanding biomanufacturing
workflows. It demonstrates ArcticZymes' ongoing commitment to enabling the
success of advanced therapeutic developers."

M-SAN HQ GMP will be available to ordering from June 16th, 2025

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh          Tel: +46 (0) 70 262 37 15
                                     ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Its headquarters are based in Tromsø, Norway, at the SIVA Science Park.
ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website:?www.arcticzymes.com